Discovery is the key to advancing human health. Find out how our leading researchers are pioneering new, breakthrough solutions to some of the world’s most challenging health problems.
The post-treatment minimal residual disease (MRD) profiles of glioblastoma patients were mapped using single cell sequencing to find a genetic signature that predicted how the cancer would recur in each individual.
About 156,000 people between the ages of 35 and 70 without a history of CVD were assessed for metabolic, behavioural and psychosocial risk factors as part of the global study.
Tohid Didar and Jeff Weitz's 'graft on a chip' allows them to test how well their innovative 'non-stick' treatment for blood vessels prevents clots from forming.
McMaster logo
